Quality Matters

JANUARY 23, 2023

Omnibus Spending Law: Provisions Will Bolster Medicines Supply Chain Insights and Advanced Manufacturing Technologies Investments to create a more resilient medicines supply chain and prepare for future public health emergencies are among key provisions of the mammoth $1.7

Generic Medicine 52

Generic Medicine Pharmaceutical Manufacturing Biosimilars Communication 52

Quality Matters

SEPTEMBER 15, 2023

For example, while some stakeholders may perceive PCM to be primarily for innovators and not for makers of generic medicines or biotech companies, it “can be for generic companies, biotechnology companies, and so on, and we have had engagements with generic drug companies in our emerging technologies program already,” Fisher said.

Generic Medicine 52

Generic Medicine Pharmaceutical Manufacturing Communication 52

Quality Matters

MAY 18, 2023

Coburn spotlighted four related objectives: Increasing manufacturing flexibility while maintaining quality and accountability; improving supply chain visibility; increasing redundancies in suppliers and decreasing supply chain length; and modernizing and optimizing stockpiling. While not specifically noted during the panel, the U.S.

Generic Medicine 52

Generic Medicine Pharmaceutical Manufacturing 52

Pharmaceutical Technology

DECEMBER 19, 2022

in 2022 to 1% in 2023 due to the “tightening of monetary and financial conditions”. Koerber-Walker discussed how the Inflation Reduction Act, introduced in 2022 , may benefit biologics companies’ funding plans going into the next year. Certain companies will struggle more than others with accruing investment from venture capital firms.

Pharmaceutical Companies 69

Pharmaceutical Companies Pharmaceutical Companies Pharmaceutical Manufacturing Generic Medicine 69